Clinical pharmacology of flurbiprofen: a novel inhibitor of platelet aggregation

Publisher Website
Google Scholar
Abstract
Studies are renewed of the inhibitory effect of flurbiprofen, given in doses ranging from 50 mg to 200 mg per day for 1 week, on platelet aggregation measured by biological tests (adenosine diphosphate and collagen methods). Flurbiprofen at doses of 50 mg and 100 mg daily had a peak time of action of between 1 and 2 hours, the effect usually disappearing after 24 hours, and 100 mg flurbiprofen caused a similar decrease in platelet aggregation to 1 g aspirin daily. In a clinical study of 72 patients with chronic glomerulonephritis treated with doses of flurbiprofen up to 200 mg daily there was a significant correlation between the parameters of aggregation measured and treatment, and between proteinuria and adenosine diphosphate aggregation when the flurbiprofen dose did not exceed 100 mg daily.